3BNC117 and 10-1074 in ART-treated Individuals

PHASE1CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

June 5, 2018

Primary Completion Date

September 30, 2021

Study Completion Date

February 11, 2022

Conditions
Human Immunodeficiency Virus
Interventions
DRUG

3BNC117

Intravenous infusion of 3BNC117

DRUG

10-1074

Intravenous infusion of 3BNC117

OTHER

Analytical treatment interruption

Analytical treatment interruption

Trial Locations (2)

10065

The Rockefeller University, New York

02114

Ragon Institute of MGH, MIT, and Harvard, Boston

All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

collaborator

Ragon Institute of MGH, MIT and Harvard

OTHER

collaborator

Montefiore Medical Center

OTHER

lead

Rockefeller University

OTHER

NCT03526848 - 3BNC117 and 10-1074 in ART-treated Individuals | Biotech Hunter | Biotech Hunter